Company intelligence / Profile preview

Libra Laboratories

San Diego, California, USAlibratechnicalcenter.com ↗

Ownership: Private
Development stage: Other

Overview

Libra Therapeutics develops novel small molecule therapeutics aimed at restoring cellular balance disrupted in neurodegenerative diseases. Their lead program targets TRPML1 and aims to enter Phase I clinical trials in 2025. Two additional programs are at the discovery/target validation stage. The company operates virtually, outsourcing all R&D to international CRO partners. No clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Axxam S.p.A. (CRO partner providing assay development and hit identification)Other unnamed international CROs handle R&D functions.

Beyond the preview

Go deeper on Libra Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Laboratories.

Explore the full profile